Sesen Bio Reports Second Quarter 2021 Financial Results and Significant Global Progress for Vicineum™
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the second quarter ended June 30,…
